A taxonomy of regulatory and policy matters relevant to psychedelic-assisted therapy in Australia
Australian & New Zealand Journal of Psychiatry April 16, 2024 Samuel P Hatfield, Nicollette Lr Thornton, Kayla Greenstien et al. 9 citations
The Australian government's recent rescheduling of psilocybin and MDMA for limited clinical use has raised regulatory challenges for psychedelic-assisted therapy. Through a desktop review, interviews with experts, and framework analysis, researchers developed a taxonomy of regulatory matters across six domains. Three domains—Service Establishment, Practitioner, and Treatment Delivery—contain many matters with uncertainty or conflicting views, such as where services should be located and which professionals qualify as therapists. The remaining domains—Patient Evaluation, Drug Supply, and Service Oversight—are relatively settled, with established regulation or consensus that regulation is unnecessary. The taxonomy offers a roadmap for health services and policymakers.